Triple-negative Breast Cancer

Learn effective strategies to lower your risk of triple-negative breast cancer recurrence after treatment. Expert guidance for your post-treatment journey.

Discover how pembrolizumab is transforming triple-negative breast cancer treatment, improving prognosis, and offering new hope beyond traditional chemotherapy.

Learn why the first five years are critical for TNBC recurrence risk. Discover how genomic testing and personalized medicine can help lower your specific risk.

Understand why TNBC requires a personalized clinical strategy. Explore genetic testing, immunotherapy, PARP inhibitors, and finding clinical trials near you.

Treatment for triple-negative breast cancer (TNBC) has changed dramatically in recent years. One of the biggest advances has been the addition of immunotherapy in both earlier-stage and metastatic TNBC. Drugs called immune checkpoint inhibitors, including pembrolizumab (Keytruda), help the immune system recognize and attack cancer cells more effectively. For many patients, these treatments have improved […]

Triple-negative breast cancer (TNBC) is one of the more challenging types of breast cancer to treat. Because it does not express estrogen, progesterone, or HER2 receptors, many targeted therapies are not effective, and treatment options are often more limited. New research from MD Anderson Cancer Center is helping explain why TNBC can be so resistant […]

If you have been diagnosed with triple-negative breast cancer (TNBC), you were probably told early on that it is “aggressive,” “fast-growing,” or “harder to treat.” You may also have been told that treatment options are limited. For years, TNBC was grouped together simply because the tumors did not express estrogen receptors, progesterone receptors, or HER2. […]

Triple-negative breast cancer (TNBC) is a complex and rapidly evolving area of breast cancer care. To help patients and caregivers better understand the latest research, we spoke with Dr. Kelly McCann, a breast medical oncologist at UCLA Health. Dr. McCann breaks down how immunotherapy is used in early-stage TNBC, why chemotherapy still plays a critical […]

The 2025 San Antonio Breast Cancer Symposium (SABCS) showcased several exciting advances in triple-negative breast cancer (TNBC). Researchers presented promising data on new treatment options, including preventive and therapeutic vaccines, targeted antibody-drug conjugates, and more. These new findings offer hope for more effective and personalized care for patients living with TNBC. See some of the […]

For Triple Negative Breast Cancer (TNBC) Day, we’re revisiting our insightful “Ask the Expert” session with Dr. Tiffany Traina at Memorial Sloan Kettering Cancer Center. Dr. Traina is an esteemed medical oncologist specializing in breast medicine and leading the TNBC clinical research program. Deepen your understanding of TNBC and watch the full replay, below. Watch […]

Essential Tips for Managing Metastatic Triple-Negative Breast Cancer When diagnosed with metastatic triple-negative breast cancer (mTNBC), you face not only physical challenges but also significant mental and emotional side effects. These “unseen” effects can be profound, particularly as you deal with mortality and the poor prognosis associated with mTNBC. These can include emotional distress and […]

Neither Outcomes4Me nor any participants in or contributors to any webinar, article or content endorses or recommends any products or services. Consult your physician regarding any treatment or therapy. An exclusive “Ask the Expert” Q&A session with the esteemed medical oncologist from Memorial Sloan Kettering Cancer Center, Dr. Tiffany Traina, a luminary in the field […]